Impact of protein stability, cellular localization, and abundance on proteomic detection of Tumor-Derived proteins in plasma

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Fang, Qiaojun ^a   Kani, Kian ^b   Faca, Vitor M ^a   Zhang, Wenxuan ^d   Zhang, Qing ^a   Jain, Anjali ^d   Hanash, Sam ^a   Agus, David B ^b   McIntosh, Martin W ^a   Mallick, Parag ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DIPEPTIDE; TUMOR PROTEIN; ANTINEOPLASTIC AGENT; PLASMA PROTEIN; PROTEOME; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN STABILITY; PROTEOMICS; QUANTITATIVE ANALYSIS; TUMOR VOLUME; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPARATIVE STUDY; DRUG RESISTANCE; METABOLISM; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; PROTEIN STABILITY; PROTEOME; PROTEOMICS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79960927847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023090     Document Type: Article

References (23)

1. Anderson NL, Anderson NG, (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867.
2. Hanash SM, Pitteri SJ, Faca VM, (2008) Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579.
3. Hawkridge AM, Muddiman DC, (2009) Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. Annu Rev Anal Chem (Palo Alto Calif) 2: 265-277.
4. Schiess R, Wollscheid B, Aebersold R, (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3: 33-44.
5. Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, et al. (2007) Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 6: 3962-3975.
6. Polanski M, Anderson NL, (2007) A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 1: 1-48.
7. Creighton C, Kuick R, Misek DE, Rickman DS, Brichory FM, et al. (2003) Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol 4: R46.
8. Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS, (2008) Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 5: e170.
9. Old W, Meyer-Arendt K, Aveline-Wolf L, Pierce K, Mendoza A, et al. (2005) Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics. Mol Cell Proteomics 4: 1487-1502.
10. Faca V, Coram M, Phanstiel D, Glukhova V, Zhang Q, et al. (2006) Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res 5: 2009-2018.
11. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383-5392.
12. Guruprasad K, Reddy BV, Pandit MW, (1990) Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng 4: 155-161.
13. McIntosh MW, Pepe MS, (2002) Combining several screening tests: optimality of the risk score. Biometrics 58: 657-664.
14. Hu S, Loo JA, Wong DT, (2006) Human body fluid proteome analysis. Proteomics 6: 6326-6353.
15. Cho JY, Sung HJ, (2009) Proteomic approaches in lung cancer biomarker development. Expert Rev Proteomics 6: 27-42.
16. Jang JH, Hanash S, (2003) Profiling of the cell surface proteome. Proteomics 3: 1947-1954.
17. Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, et al. (2007) Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 6: 3558-3565.
18. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.
19. Wang H, Clouthier SG, Galchev V, Misek DE, Duffner U, et al. (2005) Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 4: 618-625.
20. Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, et al. (2008) Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 7: 1481-1489.
21. Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, et al. (2006) Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 5: 112-121.
22. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646-4658.
23. Fang Q, Strand A, Law W, Faca VM, Fitzgibbon MP, et al. (2008) Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington's disease. Mol Cell Proteomics.